Humanigen Announces Participation and Presentation at Multiple Conferences in September
September 14 2021 - 12:56PM
Business Wire
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage
biopharmaceutical company focused on preventing and treating an
immune hyper-response called ‘cytokine storm,’ announced that
management will present and participate at multiple virtual
investor conferences in September 2021. Details of the conferences
are as follows:
Baird Global Healthcare Conference
Cameron Durrant, Chairman & CEO, will provide a corporate
update at 5:30pm EDT on September 14, 2021. Access is limited, by
the host of the conference, on an invitation only basis. Please
contact your Baird representative for information on how to access
the meeting.
H.C. Wainwright 23rd Annual Global Investment
Conference
Cameron Durrant, Chairman & CEO participated in a panel to
discuss “Best Practices Planning for the Next Pandemic”, which was
pre-recorded and will be available starting at 12pm EDT on
September 15, 2021.
Webcast:
https://journey.ct.events/view/df4da74c-0a2c-499c-a5be-13f994a0d28f
Oppenheimer Fall Healthcare Life Sciences & MedTech
Summit
Presentation date: September 22, 2021 Presentation time: 2:05
ET
Webcast: Webcast link:
https://wsw.com/webcast/oppenheimer16/hgen/2752454 The webcast will
be archived for 90 days under the Investor Relations section of the
company’s website at www.humanigen.com.
Cantor Global Healthcare 2021
Presentation date: September 27, 2021 Presentation time: 4:40
ET
Webcast link: https://wsw.com/webcast/cantor12/hgen/2064020 The
webcast will be archived for 90 days under the Investor Relations
section of the company’s website at www.humanigen.com.
About Humanigen
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage
biopharmaceutical company focused on preventing and treating an
immune hyper-response called ‘cytokine storm’. Lenzilumab is a
first-in class antibody that binds to and neutralizes
granulocyte-macrophage colony-stimulating factor (GM-CSF). Results
from preclinical models indicate GM-CSF is an upstream regulator of
many inflammatory cytokines and chemokines involved in the cytokine
storm. Early in the COVID-19 pandemic, investigation showed high
levels of GM-CSF secreting T cells were associated with disease
severity and intensive care unit admission. Humanigen’s Phase 3
LIVE-AIR study suggests early intervention with lenzilumab may
prevent consequences of a full-blown cytokine storm in hospitalized
patients with COVID-19. Humanigen has submitted lenzilumab to
Medicines and Health Regulatory Agency in the United Kingdom for a
rolling review towards potential Marketing Authorization. Humanigen
is developing lenzilumab as a treatment for cytokine storm
associated with COVID-19 and, CD19-targeted CAR-T cell therapies,
and exploring the effectiveness of lenzilumab in other inflammatory
conditions such as acute Graft versus Host Disease in patients
undergoing allogeneic hematopoietic stem cell transplantation,
eosinophilic asthma, and rheumatoid arthritis. For more
information, visit www.humanigen.com and follow Humanigen on
LinkedIn, Twitter, and Facebook.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment, and expectations regarding future
performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct, and
you should be aware that actual events or results may differ
materially from those contained in the forward- looking statements.
Words such as "will," "expect," "intend," "plan," "potential,"
"possible," "goals," "accelerate," "continue," and similar
expressions identify forward-looking statements, including, without
limitation, statements regarding our plans relating to
lenzilumab.
Forward-looking statements are subject to a number of risks and
uncertainties including, but not limited to, the risks inherent in
our lack of profitability and need for additional capital to grow
our business; our dependence on partners to further the development
of our product candidates; the uncertainties inherent in the
development, attainment of the requisite regulatory authorizations
and approvals and launch of any new pharmaceutical product; the
outcome of pending or future litigation; and the various risks and
uncertainties described in the "Risk Factors" sections of our
latest annual and quarterly reports and other filings with the
SEC.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not rely upon any
forward-looking statements as predictions of future events. We
undertake no obligation to revise or update any forward-looking
statements made in this presentation to reflect events or
circumstances after the date hereof, to reflect new information or
the occurrence of unanticipated events, to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, in each case, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210914005963/en/
Humanigen Investor Relations Ken Trbovich Humanigen
trbo@humanigen.com 650-410-3206
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Mar 2023 to Mar 2024